J. Connor Seabrook is a Partner with Alliance Technology Ventures and has worked with several of ATV’s portfolio companies. As Director of Finance & Administration, he helped AtheroGenics during its early stage raise $50 million over five years for R&D and oversaw the construction of its facilities. He also served as CFO for Inhibitex, Helios Health and Somatocor Pharmaceuticals.
Prior to joining Alliance at its inception in 1993, Mr. Seabrook was the CFO for Aspen Venture Partners, a $150 million early stage venture capital partnership. Earlier, he was an Associate with 3i Ventures in Boston. Before joining 3i Ventures, he worked at Goldman, Sachs & Co., and served as a lending officer at The United States Trust Company of New York. Mr. Seabrook received his MBA from The Amos Tuck School of Business Administration at Dartmouth College in 1985, and his Bachelor of Science in Environmental Studies and Economics from Trinity College in 1980.